Chen et al. demonstrated that the EGFR/NEAT1/EZH2/β-catenin axis in GBM bestowed an oncogenic activity in GBM that is of novel therapeutic potential (Figure 2) [104]. This evidence concerns the gene EGFR and glioblastoma.